Healthpeak Properties, Inc. is a Standard & Poor’s (“S&P”) 500 company that owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States (“U.S.”). Our company was originally founded in 1985. We are organized as an umbrella partnership REIT (“UPREIT”). We hold substantially all of our assets and conduct our operations through our operating subsidiary, Healthpeak OP, a consolidated subsidiary of which we are the managing member. We are a Maryland corporation and qualify as a self-administered REIT. We are headquartered in Denver, Colorado, with additional corporate offices in California, Tennessee, Wisconsin, and Massachusetts and property management offices in several locations throughout the U.S. We have a diversified portfolio of high-quality healthcare properties across three core asset classes of outpatient medical, lab, and continuing care retirement community (“CCRC”) real estate. Under the outpatient medical and lab segments, we own, operate, and develop outpatient medical buildings, hospitals, and lab buildings. Under the CCRC segment, our properties are operated through RIDEA structures. We have other non-reportable segments that are comprised primarily of: (i) an interest in an unconsolidated joint venture that owns 19 senior housing assets (our “SWF SH JV”), (ii) loans receivable, and (iii) a preferred equity investment. These non-reportable segments have been presented on a combined basis herein. At September 30, 2025, our portfolio of investments, including properties in certain of our unconsolidated joint ventures, consisted of interests in 703 properties: (i) Outpatient medical – 530 properties; (ii) Lab – 139 properties; (iii) CCRC – 15 properties; and (iv) Other non-reportable – 19 properties.
Healthcare REIT Titan | Explore Healthpeak's strategic positioning in life sciences, medical offices, and continuing care communities, showcasing its resilience in the evolving healthcare real estate secto |
Financial Fortitude | Delve into Healthpeak's impressive 41-year dividend streak and robust balance sheet, supporting up to $1 billion in investments amid market fluctuations |
Strategic Growth | Uncover Healthpeak's proactive approach to merger integration, capital recycling, and prudent development strategies, particularly in high-demand life sciences markets |
Market Outlook | Analysts project price targets ranging from $19 to $28, reflecting optimism about Healthpeak's potential for re-development earnings upside and strategic market positioning |
Metrics to compare | DOC | Sector Sector - Average of metrics from a broad group of related Real Estate sector companies | Relationship RelationshipDOCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −322.7x | 9.7x | 9.2x | |
PEG Ratio | 2.89 | 0.06 | 0.01 | |
Price/Book | 1.7x | 0.7x | 0.9x | |
Price / LTM Sales | 4.6x | 8.4x | 3.9x | |
Upside (Analyst Target) | 10.6% | 11.6% | 12.6% | |
Fair Value Upside | Unlock | −7.9% | 0.6% | Unlock |